Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96−0.10 (-1.24%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Novavax operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Novavax's operating cash flow for the twelve months ending Jun 30, 2026 was -$36.90M. For fiscal 2025 it was -$244.64M. The highest annual figure on record is $322.95M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$244.64M | – |
| FY2024 | Dec 31, 2024 | -$87.26M | – |
| FY2023 | Dec 31, 2023 | -$713.97M | – |
| FY2022 | Dec 31, 2022 | -$415.94M | -228.8% |
| FY2021 | Dec 31, 2021 | $322.95M | – |
| FY2020 | Dec 31, 2020 | -$42.54M | – |
| FY2019 | Dec 31, 2019 | -$136.62M | – |
| FY2018 | Dec 31, 2018 | -$184.83M | – |
| FY2017 | Dec 31, 2017 | -$144.48M | – |
| FY2016 | Dec 31, 2016 | -$258.77M | – |
| FY2015 | Dec 31, 2015 | -$126.09M | – |
| FY2014 | Dec 31, 2014 | -$67.01M | – |
| FY2013 | Dec 31, 2013 | -$45.36M | – |
| FY2012 | Dec 31, 2012 | -$18.23M | – |
| FY2011 | Dec 31, 2011 | -$23.63M | – |
| FY2010 | Dec 31, 2010 | -$32.85M | – |
| FY2009 | Dec 31, 2009 | -$32.83M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$72.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$39.48M | – |
| Q3 FY2025 | Sep 30, 2025 | $107.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$127.46M | -140.6% |
| Q1 FY2025 | Mar 31, 2025 | -$185.50M | – |
| Q4 FY2024 | Dec 31, 2024 | -$173.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$144.81M | – |
| Q2 FY2024 | Jun 30, 2024 | $314.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$83.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$176.78M | – |
| Q3 FY2023 | Sep 30, 2023 | -$39.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$171.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$325.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$117.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$38.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$170.90M | -218.3% |
| Q1 FY2022 | Mar 31, 2022 | -$88.51M | -113.3% |
| Q4 FY2021 | Dec 31, 2021 | -$342.41M | – |
| Q3 FY2021 | Sep 30, 2021 | -$142.14M | – |
| Q2 FY2021 | Jun 30, 2021 | $144.41M | +24.9% |
| Q1 FY2021 | Mar 31, 2021 | $663.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$128.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $115.63M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$32.26M | – |
| Q2 FY2019 | Jun 30, 2019 | -$30.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$50.61M | – |
| Q4 FY2018 | Dec 31, 2018 | -$45.27M | – |
| Q3 FY2018 | Sep 30, 2018 | -$33.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.97M | – |
| Q1 FY2018 | Mar 31, 2018 | -$66.08M | – |
| Q4 FY2017 | Dec 31, 2017 | -$43.40M | – |
| Q3 FY2017 | Sep 30, 2017 | -$44.18M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.40M | – |
| Q1 FY2017 | Mar 31, 2017 | -$44.50M | – |
| Q4 FY2016 | Dec 31, 2016 | -$64.55M | – |
| Q3 FY2016 | Sep 30, 2016 | -$62.36M | – |
See a number that looks wrong?